AbbVie Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 42 out of 156 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 252.33.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Media Coverage
AbbVie Inc. is an American pharmaceutical firm based in North Chicago, Illinois. Its prominent products include Humira, which is approved for treating autoimmune diseases such as rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis, and is administered through injection; Skyrizi, an interleukin-23 inhibitor also aimed at treating autoimmune disorders; Rinvoq, utilized for arthritis management; and Botox. Other significant offerings comprise Imbruvica for cancer treatment, Vraylar for schizophrenia and bipolar disorder, Venclexta for leukemia and lymphoma, and Mavyret for Hepatitis C treatment. The company is also dedicated to advancing therapies for additional conditions such as cancer, neurologic diseases, eye care, and cystic fibrosis.
AbbVie is ranked sixth among the largest biomedical companies by revenue and holds the 108th position on the Forbes Global 2000 list.
The name "AbbVie" originates from a combination of "Abbott," the name of its former parent company, and "vie," which refers to a Latin root meaning 'life.'
The current financial score of AbbVie Inc is 8.73, ranking 24 out of 156 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 15.00B, representing a year-over-year increase of 12.43%, while its net profit experienced a year-over-year increase of 45.53%.
Key Metrics
The current valuation score of AbbVie Inc is 5.05, ranking 151 out of 156 in the Pharmaceuticals industry. Its current P/E ratio is 98.93, which is 79.94% below the recent high of 178.02 and 78.03% above the recent low of 21.74.
The current earnings forecast score of AbbVie Inc is 7.94, ranking 95 out of 156 in the Pharmaceuticals industry. The average price target is 245.00, with a high of 289.00 and a low of 187.64.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
The current price momentum score of AbbVie Inc is 7.33, ranking 57 out of 156 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 214.03 and the support level at 189.91, making it suitable for range-bound swing trading.
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
The current institutional shareholding score of AbbVie Inc is 7.00, ranking 47 out of 156 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 76.46%, representing a quarter-over-quarter increase of 2.13%. The largest institutional shareholder is The Vanguard, holding a total of 172.78M shares, representing 9.77% of shares outstanding, with 0.35% decrease in holdings.
The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of AbbVie Inc is 9.20, ranking 13 out of 156 in the Pharmaceuticals industry. The company's beta value is 0.30. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
